Correlation between inhibited gastric secretion level and residual symptoms in GERD patients refractory to PPI

Correlation between inhibited gastric secretion level and residual symptoms in GERD patients refractory to PPI - Correlation between inhibited gastric secretion level and residual symptoms in GERD patients refractory to PPI

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017347

Enrollment

200

Registered

2015-06-01

Start date

2014-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GERD patients on ordinary dose of PPI

Interventions

PPI treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: GERD patients on ordinary dose of PPI

Exclusion criteria

Exclusion criteria: 1. PPI compliance lower that 90% 2. taking other anti-secretory drugs, prokinetics, or anti-psychotis 3. GERD afer upper GI surgery 4. long-segment (more than 3 cm) Barrett's esophagus 5. taking NSAIDs or aspirin 6 receiving H. pylori eradication within 1 year 7. serious systematic diseases

Design outcomes

Primary

Measure	Time frame
Comparison of gastric acid secretion during PPI administration between GERD patients with and those without residual symptoms	—

Countries

Japan

Contacts

Public ContactKatsunori Iijima

Tohuku University Hospital Division of Gastroenterology

kiijima@med.tohoku.ac.jp022-717-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026